BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
PROPEL 3, the Phase 3 clinical trial of infigratinib in achondroplasia, successfully achieved its pre-specified primary efficacy endpoint of change from baseline in absolute height velocity (AHV) at ...
BridgeBio (BBIO) reported Q4 2025 results yesterday. There were no major surprises since the company pre-announced the results last month ahead of the JP Morgan Healthcare conference, but we still saw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results